Press coverage about ProNAi Therapeutics (NASDAQ:SRRA) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.9281396709145 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of research analysts recently weighed in on the company. Zacks Investment Research lowered ProNAi Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Jefferies Group LLC raised ProNAi Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, October 23rd. Finally, ValuEngine raised ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $4.00.

ProNAi Therapeutics (SRRA) remained flat at $$1.99 during mid-day trading on Monday. The company had a trading volume of 272,691 shares, compared to its average volume of 605,816.

ProNAi Therapeutics (NASDAQ:SRRA) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. sell-side analysts expect that ProNAi Therapeutics will post -0.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact ProNAi Therapeutics (SRRA) Share Price” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-pronai-therapeutics-srra-share-price/1683954.html.

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for ProNAi Therapeutics (NASDAQ:SRRA)

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.